Aktienanalyse zu TriSalus Life Sciences Inc (TLSI)

$3.890

+0.458 (+11.78%)Zum Schluss

Loading chart…

Hoch: 4.000
Eröffnung: 3.600
Volumengewichteter Durchschnittskurs: 3.83
Volumen: 232.27K
Marktkap.: 156.44M
Tief: 3.600
Umsatz: 889.61K
EV/EBITDA, TTM: -3.19

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.

trisaluslifesci.com

KI-Analyse of TriSalus Life Sciences Inc (TLSI)

Halten

TriSalus Life Sciences Inc is currently not a strong buy due to its low current price of $3.63 and an RSI of 36.448, indicating potential oversold conditions. However, the stock has a significant upside potential with analysts projecting a price target of $12, which suggests a potential upside of over 230%. The main risk is its high debt to equity ratio of 504.81%, indicating financial instability that could affect future performance.

Bewertungskennzahlen

Das aktuelle erwartete KGV von TriSalus Life Sciences Inc (TLSI) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -5.35.

Erwartetes KGV

Fair bewertet

5J-Durchschnitt P/E

-5.35

Aktuelles P/E

0.00

Überbewertet

0.43

Unterbewertet

-11.14

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

-11.34

Aktuelles EV/EBITDA

-3.19

Überbewertet

10.81

Unterbewertet

-33.50

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

3.76

Aktuelles P/S

2.88

Überbewertet

6.72

Unterbewertet

0.79

Alphio-AI-Kursszenarien für TLSI

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

Bullisch

Bullisch · 25%TLSI

$9.17

Szenariopreis

Basis

Basis · 50%TLSI

$6.96

Szenariopreis

Bärisch

Bärisch · 25%TLSI

$5.01

Szenariopreis